Eliezer Van Allen

About Eliezer Van Allen
  • The introduction of Zytiga and Xtandi into standard of care for advanced, metastatic prostate cancer benefits many patients; however, all will ultimately become resistant to these medicines.
  • Resistance mechanisms to these treatments remain mainly unknown.
  • Dr. Van Allen will interrogate numerous potential resistance mechanisms by determining genomic alterations that occur prior to, and after resistance to Zytiga.

What this means for patients: Understanding mechanisms of resistance to Zytiga should result in the identification of new therapeutic targets for the treatment of drug-resistant, advanced, metastatic prostate cancer.

Award

2013 Albert Fuss PCF Young Investigator Sponsored by Mark Shenkman

Eliezer Van Allen, MD

Dana-Farber Cancer Center

Mentor:

Levi Garraway, MD, PhD

Project Title:

Dissecting clinical response and resistance to abiraterone acetate (Zytiga)